Featured Press Releases

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

FDA approves Apellis

FDA approves Apellis' EMPAVELI® (pegcetacoplan) as the first treatment for patients aged 12 and older with C3G and primary IC-MPGN

  • 30 Jul 2025

Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

PharmAbcine

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

IKA introduces new accessories for the HABITAT research bioreactor.

IKA introduces new accessories for the HABITAT research bioreactor.

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

New Study Suggests 5-MTHF as Effective Alternative to Folic Acid in Later Pregnancy

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
SEREMI de Salud Grants Registration to Chile

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

  • Kyowa Hakko U.S.A
  • 11 Jun 2026
Roquette Highlights Scalable Innovations in Drug Delivery

Roquette Highlights Scalable Innovations in Drug Delivery

  • Roquette
  • 11 Jun 2026
X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

  • X-Therma Inc.
  • 11 Jun 2026
IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

  • Johnson & Johnson
  • 10 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.